Bone Marrow Transplantation - Table of Contents alert Volume 51 Issue 7

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 51, Issue 7 (July 2016) In this issue Reviews Special Report Commentaries Original Articles Letters to the Editor Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Benefits of publishing in Human Genome Variation (HGV) - Quality peer-review and fast decision times - Research Summaries to enhance the reach of your work - High visibility for your research  Submit your research today and contribute to this exciting journal!   Reviews Top Post-bone marrow transplant thrombotic microangiopathy F Obut, V Kasinath and R Abdi Bone Marrow Transplant 2016 51: 891-897; advance online publication, March 14, 2016; 10.1038/bmt.2016.61 Abstract | Full Text Haematopoietic cell transplants in Latin America R P Gale, A Seber, C Bonfim and M Pasquini Bone Marrow Transplant 2016 51: 898-905; advance online publication, March 21, 2016; 10.1038/bmt.2016.35 Abstract | Full Text Special Report Top Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation OPEN M Mohty, F Malard, M Abecassis, E Aerts, A S Alaskar, M Aljurf, M Arat, P Bader, F Baron, A Bazarbachi, D Blaise, F Ciceri, S Corbacioglu, J-H Dalle, F Dignan, T Fukuda, A Huynh, T Masszi, M Michallet, A Nagler, M NiChonghaile, S Okamoto, A Pagliuca, C Peters, F B Petersen, P G Richardson, T Ruutu, B N Savani, E Wallhult, I Yakoub-Agha, R F Duarte and E Carreras Bone Marrow Transplant 2016 51: 906-912; advance online publication, May 16, 2016; 10.1038/bmt.2016.130 Abstract | Full Text Commentaries Top MRD-driven treatment paradigm for newly diagnosed transplant eligible multiple myeloma patients O Landgren and S Giralt Bone Marrow Transplant 2016 51: 913-914; advance online publication, February 29, 2016; 10.1038/bmt.2016.24 Full Text The devil is in the T cells: relapsing after haploidentical hematopoietic cell transplantation M Byrne and B N Savani Bone Marrow Transplant 2016 51: 915-918; advance online publication, April 18, 2016; 10.1038/bmt.2016.106 Full Text Pretransplant conditioning with fludarabine and IV busulfan, reduced toxicity and increased safety without compromising antitumor efficacy and overall treatment effect? B S Andersson and B C Valdez Bone Marrow Transplant 2016 51: 919-920; advance online publication, April 25, 2016; 10.1038/bmt.2016.110 Full Text Original Articles Top ACUTE LEUKEMIA Predictive value of high EVI1 expression in AML patients undergoing myeloablative allogeneic hematopoietic stem cell transplantation in first CR X He, Q Wang, J Cen, H Qiu, A Sun, S Chen and D Wu Bone Marrow Transplant 2016 51: 921-927; advance online publication, April 4, 2016; 10.1038/bmt.2016.71 Abstract | Full Text LYMPHOMA Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC) A Stamatoullas, P Brice, M S Gueye, S Mareschal, P Chevallier, R Bouabdallah, S Nguyenquoc, S Francois, P Turlure, P Ceballos, H Monjanel, J-H Bourhis, G Guillerm, M Mohty, P Biron, J Cornillon, K Belhadj, C Bonmati, M-S Dilhuydy, A Huynh, M Bernard, M-L Chrétien, R Peffault de Latour and H Tilly Bone Marrow Transplant 2016 51: 928-932; advance online publication, April 4, 2016; 10.1038/bmt.2016.76 Abstract | Full Text PLASMA CELL DISORDERS Early relapse post autologous transplant is a stronger predictor of survival compared with pretreatment patient factors in the novel agent era: analysis of the Singapore Multiple Myeloma Working Group S Y Ong, S de Mel, Y X Chen, M G Ooi, S Surendran, A Lin, L P Koh, Y C Linn, A Y L Ho, W Y K Hwang, C Phipps, S M Y Loh, Y T Goh, D Tan, W J Chng and S K Gopalakrishnan Bone Marrow Transplant 2016 51: 933-937; advance online publication, March 14, 2016; 10.1038/bmt.2016.43 Abstract | Full Text INHERITED AND GENETIC DISORDERS Late effects in patients with Fanconi anemia following allogeneic hematopoietic stem cell transplantation from alternative donors P Anur, D N Friedman, C Sklar, K Oeffinger, M Castiel, J Kearney, B Singh, S E Prockop, N A Kernan, A Scaradavou, R Kobos, K Curran, J Ruggiero, N Zakak, R J O'Reilly and F Boulad Bone Marrow Transplant 2016 51: 938-944; advance online publication, March 21, 2016; 10.1038/bmt.2016.32 Abstract | Full Text SOLID CANCERS Decreased morbidity and mortality of autologous hematopoietic transplants for children with malignant central nervous system tumors: the ‘Head Start’ trials, 1991–2009 C Altshuler, K Haley, G Dhall, L Vasquez, S L Gardner, J Stanek and J L Finlay for the ‘Head Start’ Consortium Bone Marrow Transplant 2016 51: 945-948; advance online publication, March 7, 2016; 10.1038/bmt.2016.45 Abstract | Full Text GRAFT SOURCE Post-relapse survival after haploidentical transplantation vs matched-related or matched-unrelated hematopoietic cell transplantation M Solh, X Zhang, K Connor, S Brown, S R Solomon, L E Morris, H K Holland and A Bashey Bone Marrow Transplant 2016 51: 949-954; advance online publication, March 21, 2016; 10.1038/bmt.2016.62 Abstract | Full Text GRAFT MANIPULATION Outcome of hematopoietic stem cell transplantation is similar for patients with a partial in vitro T-cell-depleted graft compared with a non-T-cell-depleted graft when stratified by the refined disease risk index Y Beauverd, E Roosnek, Y Tirefort, C Dantin, M Ansari, O Tsopra, S Masouridi-Levrat and Y Chalandon Bone Marrow Transplant 2016 51: 955-960; advance online publication, March 7, 2016; 10.1038/bmt.2016.34 Abstract | Full Text CONDITIONING Toxicity and efficacy of busulfan and fludarabine myeloablative conditioning for HLA-identical sibling allogeneic hematopoietic cell transplantation in AML and MDS J De La Serna, J Sanz, A Bermúdez, M Cabrero, D Serrano, C Vallejo, V Gómez, J M Moraleda, S G Perez, M D Caballero, E Conde, J J Lahuerta and G Sanz on behalf of the A GETH (Grupo Español de Trasplante Hematopoyético y Terapia Celular—Spanish Hematopoietic Transplant and Cell Therapy Group) Study Bone Marrow Transplant 2016 51: 961-966; advance online publication, March 7, 2016; 10.1038/bmt.2016.42 Abstract | Full Text TRANSPLANT TOXICITIES Personalized home-based interval exercise training may improve cardiorespiratory fitness in cancer patients preparing to undergo hematopoietic cell transplantation W A Wood, B Phillips, A E Smith-Ryan, D Wilson, A M Deal, C Bailey, M Meeneghan, B B Reeve, E M Basch, A V Bennett, T C Shea and C L Battaglini Bone Marrow Transplant 2016 51: 967-972; advance online publication, March 21, 2016; 10.1038/bmt.2016.73 Abstract | Full Text Blood glucose control using a computer-guided glucose management system in allogeneic hematopoietic cell transplant recipients C Espina, I Jenkins, L Taylor, R Farah, E Cho, J Epworth, K Coleman, J Pinelli, S Mentzer, L Jarrett, T Gooley, P O'Donnell, I B Hirsch and M Bar Bone Marrow Transplant 2016 51: 973-979; advance online publication, April 4, 2016; 10.1038/bmt.2016.78 Abstract | Full Text QOL AND PATIENTS' CARE Poor growth, thyroid dysfunction and vitamin D deficiency remain prevalent despite reduced intensity chemotherapy for hematopoietic stem cell transplantation in children and young adults K C Myers, J C Howell, G Wallace, C Dandoy, J El-Bietar, A Lane, S M Davies, S Jodele and S R Rose Bone Marrow Transplant 2016 51: 980-984; advance online publication, March 14, 2016; 10.1038/bmt.2016.39 Abstract | Full Text Letters to the Editor Top Feasibility of salvage cord blood transplantation following fludarabine, melphalan and low-dose TBI for graft rejection after hematopoietic stem cell transplantation K Ishiyama, J Takeda, T Kondo, N Sugimoto, H Kawabata, T Kitano and A Takaori-Kondo Bone Marrow Transplant 2016 51: 985-987; advance online publication, February 15, 2016; 10.1038/bmt.2016.16 Full Text Efficacy of narrow band UVB in the treatment of cutaneous GvHD: an Indian experience L George, D Peter, M Chopra, B George, A Abraham, V Mathews, A Srivastava and S A Pulimood Bone Marrow Transplant 2016 51: 988-990; advance online publication, February 22, 2016; 10.1038/bmt.2016.13 Full Text Low incidence of GvHD with T-cell depleted allografts facilitates further treatments for post-transplantation relapse in AML and MDS P B Dahi, E Morawa, M-A Perales, E C Zabor, S M Devlin, M Maloy, H Castro-Malaspina, R J O'Reilly, E B Papadopoulos, A A Jakubowski and S A Giralt Bone Marrow Transplant 2016 51: 991-993; advance online publication, February 29, 2016; 10.1038/bmt.2016.23 Full Text Strong impact of extramedullary involvement in high-risk AML patients with active disease receiving the FLAMSA conditioning regimen for HSCT OPEN S Bohl, S von Harsdorf, M Mulaw, S Hofmann, A Babiak, C P Maier, J Schnell, L-M Hütter-Krönke, K Scholl, V Wais, R F Schlenk, L Bullinger, M Ringhoffer, H Döhner, D Bunjes, M Bommer and F Kuchenbauer Bone Marrow Transplant 2016 51: 994-996; advance online publication, March 7, 2016; 10.1038/bmt.2016.4 Full Text Gonadal shielding technique to preserve fertility in male pediatric patients treated with total body irradiation for stem cell transplantation M Sayan, R J Cassidy, E E Butker, R H Nanda, L Krishnamurti, M K Khan and N Esiashvili Bone Marrow Transplant 2016 51: 997-998; advance online publication, March 7, 2016; 10.1038/bmt.2016.25 Full Text Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation A Varma, R M Saliba, H A Torres, A Afrough, C Hosing, I F Khouri, Y Nieto, N D Shah, S Parmar, Q Bashir, S Ahmed, R B Jones, P Kebriaei, A L Olson, E J Shpall, A M Alousi, M H Qazilbash, R E Champlin and U Popat Bone Marrow Transplant 2016 51: 999-1001; advance online publication, March 7, 2016; 10.1038/bmt.2016.28 Full Text Autologous and allogeneic stem cell transplant in Jehovah’s Witnesses: a single-center experience on 22 patients P Mazza, G Palazzo, C Minoia, B Amurri and G Pisapia Bone Marrow Transplant 2016 51: 1002-1003; advance online publication, March 7, 2016; 10.1038/bmt.2016.29 Full Text Regionalization of stem cell transplant procedures into teaching hospitals in United States: are we ready? V Allareddy, S Rampa, N Martinez-Schlurmann, R P Nalliah and V Allareddy Bone Marrow Transplant 2016 51: 1004-1006; advance online publication, March 7, 2016; 10.1038/bmt.2016.33 Full Text An intra-patient comparison of blood cell separators Spectra and Optia in patients and donors undergoing blood mononuclear cell collections at a single institution for subsequent autologous or allogeneic hematopoietic cell transplantation reveals comparable collection efficiencies A Drezet, A Granata, C Lemarie, B Calmels and C Chabannon Bone Marrow Transplant 2016 51: 1007-1009; advance online publication, March 7, 2016; 10.1038/bmt.2016.41 Full Text A novel reduced intensity conditioning regimen for patients with high-risk hematological malignancies undergoing allogeneic stem cell transplantation G S Hobbs, N Kaur, P Hilden, D Ponce, C Cho, H R Castro-Malaspina, S Giralt, J D Goldberg, A A Jakubowski, E B Papadopoulos, C Sauter, G Koehne, J Yahalom, S Delvin, J N Barker and M-A Perales Bone Marrow Transplant 2016 51: 1010-1012; advance online publication, March 14, 2016; 10.1038/bmt.2016.36 Full Text Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary J M Watts, X V Wang, R T Swords, E Paietta, D Douer, S M Lugar, H F Fernandez, J M Rowe, H M Lazarus, M S Tallman and M R Litzow Bone Marrow Transplant 2016 51: 1013-1015; advance online publication, March 14, 2016; 10.1038/bmt.2016.44 Full Text Inadvertent completely HLA-mismatched allogeneic unrelated bone marrow transplant: lessons learned B S Sorensen, J Szer, B Shaw, M Korhonen, T Mengling, M Fechter, H Elmoazzen, B Lindberg, J Chapman, J M Nørgaard, L Foeken, W Y K Hwang and B Nielsen Bone Marrow Transplant 2016 51: 1016-1018; advance online publication, March 14, 2016; 10.1038/bmt.2016.59 Full Text Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study F V Michelis, E G Atenafu, S Couban, J Frazer, S Shivakumar, D E Hogge, C L Toze, W Rajkhan, H J Kim, A Daly, J Slaby, J Finke, T Kiss, C Bredeson, M Sabloff, D Sheppard, M Bakkar, M Brune, D A Wall, K Paulson, G Popradi, I Walker and H A Messner Bone Marrow Transplant 2016 51: 1019-1021; advance online publication, March 14, 2016; 10.1038/bmt.2016.60 Full Text Coadministration of posaconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients R Greco, M C Barbanti, MT Lupo Stranghellini, F Giglio, M Morelli, C Messina, A Forcina, C Oltolini, S Piemontese, P Scarpellini, S Marktel, A Assanelli, M Carrabba, L Vago, C Corti, M Bernardi, J Peccatori and F Ciceri Bone Marrow Transplant 2016 51: 1022-1024; advance online publication, April 25, 2016; 10.1038/bmt.2016.112 Full Text Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Bone Marrow Transplantation. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.